Whitehawk Therapeutics (WHWK) Cost of Revenue (2022 - 2025)
Whitehawk Therapeutics (WHWK) reported Cost of Revenue of $760000.0 for Q1 2025, up 16.56% year-over-year from $652000.0 in Q1 2024, and down 3.8% on a QoQ basis from $790000.0 in Q4 2024.
Whitehawk Therapeutics (WHWK) has 4 years of Cost of Revenue data on file, last reported at $760000.0 in Q1 2025.
- Quarterly Cost of Revenue rose 16.56% year-over-year to $760000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $760000.0 (down 74.87% YoY) and the FY2025 annual result came in at $760000.0, down 74.87% from the prior year.
- Cost of Revenue eased to $760000.0 in Q1 2025 per WHWK's latest filing, from $790000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $927000.0 in Q4 2023 and bottomed at $179000.0 in Q1 2022.
- The 4-year median for Cost of Revenue is $656000.0 (2023), against an average of $609846.2.
- The widest annual swing landed in 2023, when Cost of Revenue surged 317.57%; it then retreated 14.78% in 2024.
- Tracing WHWK's Cost of Revenue over 4 years: stood at $222000.0 in 2022, then jumped by 317.57% to $927000.0 in 2023, then dropped by 14.78% to $790000.0 in 2024, then retreated by 3.8% to $760000.0 in 2025.
- Per Business Quant, the three latest WHWK Cost of Revenue figures stand at $760000.0 (Q1 2025), $790000.0 (Q4 2024), and $804000.0 (Q3 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 296.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 207.52 Mn |
| 10 | Whitehawk Therapeutics | 312.26 Mn | 189.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 760,000.00 |
| Mar 31, 2025 | 760,000.00 |
| Dec 31, 2024 | 790,000.00 |
| Dec 31, 2024 | 790,000.00 |
| Sep 30, 2024 | 804,000.00 |
| Sep 30, 2024 | 804,000.00 |
| Jun 30, 2024 | 778,000.00 |
| Jun 30, 2024 | 778,000.00 |
| Mar 31, 2024 | 652,000.00 |
| Mar 31, 2024 | 652,000.00 |
| Dec 31, 2023 | 927,000.00 |
| Dec 31, 2023 | 927,000.00 |
| Sep 30, 2023 | 697,000.00 |
| Sep 30, 2023 | 697,000.00 |
| Jun 30, 2023 | 656,000.00 |
| Jun 30, 2023 | 656,000.00 |
| Mar 31, 2023 | 529,000.00 |
| Mar 31, 2023 | 529,000.00 |
| Dec 31, 2022 | 222,000.00 |
| Dec 31, 2022 | 222,000.00 |
| Sep 30, 2022 | 593,000.00 |
| Sep 30, 2022 | 593,000.00 |
| Jun 30, 2022 | 341,000.00 |
| Jun 30, 2022 | 341,000.00 |
| Mar 31, 2022 | 179,000.00 |
| Mar 31, 2022 | 179,000.00 |